VIVUS (Nasdaq: VVUS) shocked the market with seemingly unbelievable first quarter results, sending shares over 10% higher. They have since steadily declined. The lesson as always: if something seems to good to be true, it probably is. 

Sales of its obesity drug Qsymia doubled, but to the still low total of $9 million. More concerning prescriptions declined, despite the aggressive discount program for the drug.

In this episode of Market Check-Up, the Motley Fool's health-care focused investing show, analysts David Williamson and Michael Douglass discuss the quarterly results, obesity drug competition, and ultimately why Vivus investors should be concerned. 



David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.